Taking into account the opposing role of STAT1 and STAT3 signaling in the development of different cardiovascular diseases as well as in neurodegenerative disorders, therapeutic strategies that target STAT1/3 S-glutathionylation may offer new promise for drug development also in combination with more standardized therapies. The gene discussed is STAT1; the disease is cardiovascular disorder.